Application of accelerated quantitative magnetic resonance imaging in predicting drug resistance in pituitary prolactinomas

Motivation: Predicting and managing dopamine agonists (DA) resistance of prolactinomas remain a challenge. There is no reliable quantitative imaging marker. Goal(s): The goal is to use accelerated quantitative T2 mapping(GRAPPATNI) for early diagnosis of drug resistance in pituitary prolactinomas to guide treatment. Approach: This is a cross-sectional study. It will analyze the differences in T2 values between drug-resistant and sensitive groups and explore their diagnostic value in predicting drug sensitivity. Results: Quantitative T2 values have better sensitivity than T2 signal intensity (SI) in predicting drug resistance in pituitary prolactinoma. Impact: This is the first study to apply GRAPPATINI in prolactinoma. We found that T2 values of tumors were lower in drug-resistant prolactinoma than sensitive patients. T2 values might be a promising predictive imaging tool.